Literature DB >> 12656907

Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease.

R M Prieto Castro1, M E Leva Vallejo, J C Regueiro Lopez, F J Anglada Curado, J Alvarez Kindelan, M J Requena Tapia.   

Abstract

OBJECTIVE: To assess the effectiveness of the combination of colchicine and vitamin E (which has anti-fibrotic, anti-mitotic and anti-inflammatory effects) in modifying the early stages of Peyronie's disease, by evaluating pain relief, correction of deformities and plaque size. PATIENTS AND METHODS: In all, 45 patients were divided into two groups and treated from January 1998 to November 2001. Their mean (range) age was 53.4 (40-62) years, the time from onset of the disease < 6 months and they had penile deformity of < 30 degrees; no patient had erectile dysfunction. Twenty-two patients were given ibuprofen 400 mg/day for 6 months, whilst 23 received a combination of vitamin E 600 mg/day plus colchicine 1 mg every 12 h. Pain, plaque size and penile deformity were assessed at 6 months.
RESULTS: There were no statistically significant differences between the groups at baseline in age, time from onset of the disease until the initial evaluation or plaque size. Although the proportion of patients reporting pain relief was higher amongst those receiving colchicine plus vitamin E (91% vs 68%) this was not significantly different, but differences in plaque size and penile curvature were significant.
CONCLUSIONS: The use of colchicine plus vitamin E during the early stages of Peyronie's disease (time from onset < 6 months) in patients with penile curvature of < 30 degrees and no erectile dysfunction is an effective and well-tolerated way to stabilize the disease. A more extensive study is needed, comparing these results with other oral therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12656907     DOI: 10.1046/j.1464-410x.2003.04134.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  [Current therapeutic options for Peyronie's disease].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

Review 2.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 3.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

Review 4.  Update on medical management of Peyronie's disease.

Authors:  Ronny B W Tan; Premsant Sangkum; Gregory C Mitchell; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

Review 5.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Colchicine for prevention of cardiovascular events.

Authors:  Lars G Hemkens; Hannah Ewald; Viktoria L Gloy; Armon Arpagaus; Kelechi K Olu; Mark Nidorf; Dominik Glinz; Alain J Nordmann; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

7.  Current and emerging treatment options for Peyronie's disease.

Authors:  Ahmet Gokce; Julie C Wang; Mary K Powers; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2013-01-14

Review 8.  The non-surgical treatment of peyronie disease: 2013 update.

Authors:  Eric James Shaw; Gregory Clyde Mitchell; Ronny B Tan; Premsant Sangkum; Wayne John G Hellstrom
Journal:  World J Mens Health       Date:  2013-12-24       Impact factor: 5.400

Review 9.  Oral therapy for Peyronie's disease, does it work?

Authors:  Brittani Barrett-Harlow; Run Wang
Journal:  Transl Androl Urol       Date:  2016-06

Review 10.  A review of the epidemiology and treatment of Peyronie's disease.

Authors:  Kevin A Ostrowski; John R Gannon; Thomas J Walsh
Journal:  Res Rep Urol       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.